- AU$142.78bn
- AU$162.16bn
- $13.31bn
- 85
- 13
- 72
- 60
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 27.97 | ||
| PEG Ratio (f) | 2.01 | ||
| EPS Growth (f) | 16.13% | ||
| Dividend Yield (f) | 1.6% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.45 | ||
| Price to Tang. Book | 131.91 | ||
| Price to Free Cashflow | 80.83 | ||
| Price to Sales | 6.6 | ||
| EV to EBITDA | 24.11 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 10.89% | ||
| Return on Equity | 15.05% | ||
| Operating Margin | 25.02% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 8,538.6 | 9,150.8 | 10,310 | 10,561.9 | 13,310 | 14,713.16 | 15,924.81 | 10.95% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +11.47 | +8.39 | +8.42 | -6.4 | -3.44 | +23.2 | +16.07 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.
Directors
- Brian McNamee NEC (64)
- Paul Perreault CEO
- Joy Linton CFO
- Paul McKenzie COO (54)
- Elizabeth Walker CHO
- Greg Boss EVP (60)
- William Campbell EVP (62)
- William Mezzanotte EVP (62)
- Alan Wills EVP
- Mark Hill CIO
- Robert Cuthbertson EDR (65)
- Fiona Mead SEC (51)
- Bruce Brook NID (66)
- Megan Clark NID (63)
- Carolyn Hewson NID (66)
- Duncan Maskell NID
- Marie McDonald NID (64)
- Alison Watkins NID
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 1st, 1991
- Public Since
- June 8th, 1994
- No. of Shareholders
- 248,407
- No. of Employees
- 32,065
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 483,093,257
- Address
- 45 Poplar Road,, Parkville, MELBOURNE, 3052
- Web
- https://www.csl.com/
- Phone
- +61 393891911
- Contact
- Bernard Ronchi
- Auditors
- Ernst & Young
Latest News for CSL
Upcoming Events for CSL
Full Year 2024 CSL Ltd Earnings Release
CSL Ltd Annual Shareholders Meeting
Similar to CSL
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
FAQ
As of Today at 20:09 UTC, shares in CSL are trading at AU$292.01. This share price information is delayed by 15 minutes.
Shares in CSL last closed at AU$292.01 and the price had moved by +3.55% over the past 365 days. In terms of relative price strength the CSL share price has underperformed the ASX All Ordinaries Index by -5.68% over the past year.
The overall consensus recommendation for CSL is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The CSL dividend yield is 1.32% based on the trailing twelve month period.
Last year, CSL paid a total dividend of $2.56, and it currently has a trailing dividend yield of 1.32%. We do not have any data on when CSL is to next pay dividends.
We do not have data on when CSL is to next pay dividends. The historic dividend yield on CSL shares is currently 1.32%.
To buy shares in CSL you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$292.01, shares in CSL had a market capitalisation of AU$141.07bn.
Here are the trading details for CSL:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: CSL
Based on an overall assessment of its quality, value and momentum CSL is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in CSL is AU$320.12. That is 9.63% above the last closing price of AU$292.01.
Analysts covering CSL currently have a consensus Earnings Per Share (EPS) forecast of $5.98 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CSL. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -0.06%.
As of the last closing price of AU$292.01, shares in CSL were trading +6.8% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The CSL PE ratio based on its reported earnings over the past 12 months is 27.97. The shares last closed at AU$292.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
CSL's management team is headed by:
- Brian McNamee - NEC
- Paul Perreault - CEO
- Joy Linton - CFO
- Paul McKenzie - COO
- Elizabeth Walker - CHO
- Greg Boss - EVP
- William Campbell - EVP
- William Mezzanotte - EVP
- Alan Wills - EVP
- Mark Hill - CIO
- Robert Cuthbertson - EDR
- Fiona Mead - SEC
- Bruce Brook - NID
- Megan Clark - NID
- Carolyn Hewson - NID
- Duncan Maskell - NID
- Marie McDonald - NID
- Alison Watkins - NID